CIP
IMVT icon

Chartwell Investment Partners’s Immunovant IMVT Stock Holding History

Chartwell Investment Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$515K Buy
18,085
+144
+0.8% +$4.25K 0.02% 399
2024
Q2 		$474K Sell
17,941
-2,924
-14% -$83.2K 0.02% 397
2024
Q1 		$674K Buy
20,865
+495
+2% +$18.1K 0.02% 390
2023
Q4 		$858K Sell
20,370
-2,756
-12% -$101K 0.03% 374
2023
Q3 		$887K Hold
23,126
– – 0.03% 361
2023
Q2 		$439K Buy
23,126
+1,122
+5% +$20.9K 0.02% 393
2023
Q1 		$341K Buy
22,004
+739
+3% +$12.8K 0.01% 398
2022
Q4 		$377K Buy
+21,265
New +$268K 0.01% 390

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Chartwell Investment Partners's IMVT Position: Q3 2024 in Review

Chartwell Investment Partners increased its Immunovant (IMVT) stake by 0.8% in Q3 2024, buying an estimated $4.25K and bringing the position to 18,085 shares worth $515K. The position accounts for 0.02% of the portfolio, ranked #399.

Chartwell Investment Partners first reported a position in IMVT in Q4 2022 and has held it in 8 quarters since. The position peaked at $887K in Q3 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Chartwell Investment Partners held 18,085 shares of Immunovant worth $515K as of Q3 2024.
  • Chartwell Investment Partners bought 144 Immunovant shares in Q3 2024, an estimated $4.25K.
  • Immunovant made up 0.02% of Chartwell Investment Partners's portfolio in Q3 2024, its #399 holding.
  • Chartwell Investment Partners first reported a position in Immunovant in Q4 2022 and has held it in 8 quarters since.
  • Chartwell Investment Partners's Immunovant position peaked at $887K in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.